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ABSTRACT The Epstein-Barr virus protein latent membrane protein 1 (LMP1) has two NF-B activating domains within its in-
tracellular carboxy terminus (carboxy-terminal activating region 1 [CTAR1] and CTAR2). LMP1-CTAR1 is required for
B-lymphocyte transformation, is capable of transforming rodent fibroblasts, and uniquely activates phosphoinositol (PI3) ki-
nase, the noncanonical NF-B pathway, and expression of the epidermal growth factor receptor (EGFR). In this study, the effects
of LMP1-CTAR1 on cellular gene expression were determined by high-throughput sequencing. Additionally, the binding of bcl3
was determined using chromatin immunoprecipitation (ChIP) and sequencing. LMP1-CTAR1 induced few changes in transcrip-
tion with more genes showing decreased expression. Ingenuity pathway analysis indicated significant enrichment for genes in-
volved in cancer and cellular movement, survival, growth, and proliferation pathways. ChIP in combination with high-
throughput sequencing (ChIP-Seq) identified bcl3 binding for more than 2,000 genes in LMP1-CTAR1-expressing cells with
more than 90% of the peaks at genes detected within the probable promoter region. Only a small subset of the genes with signifi-
cant changes in expression had corresponding peaks in the bcl3 ChIP. However, both NFKB2 and PI3 kinase were identified in
the bcl3 ChIP. Additionally, many of the predicted upstream regulators for the changes in expression were identified in the bcl3
ChIP. Analysis of the proteins in the NF-B pathway revealed many changes identified by the high-throughput RNA sequencing
(RNA-Seq) and bcl3 ChIP that would likely activate noncanonical NF-B signaling and possibly inhibit canonical NF-B signal-
ing. These findings suggest that the two LMP1 signaling domains modulate their combined activity and that the bcl3 transcrip-
tion factor is likely responsible for some of the unique effects of CTAR1 on cellular expression.
IMPORTANCE The Epstein-Barr virus protein latent membrane protein 1 (LMP1) has potent effects on cell growth. LMP1 has
two regions, carboxy-terminal activating region 1 (CTAR1) and CTAR2, that distinctly activate NF-B, a transcription factor
complex involved in activation of important host genes. In this study, analysis of the effects on cellular gene expression revealed
that CTAR1 significantly affected cellular expression in part through effects on a specific form of NF-B. The data suggest that
LMP1 can activate a distinct subset of host gene expression through its CTAR1 domain which in combination with other signal-
ing effects induced by the CTAR2 domain likely affects cell movement, survival, and growth.
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The Epstein-Barr virus (EBV) infects both lymphoid and epi-thelial cells and is associated with distinct malignancies that
develop in both cell types (1). EBV is consistently detected within
all cells of the major malignancy nasopharyngeal carcinoma
(NPC), and the viral oncoprotein latent membrane protein 1
(LMP1) is frequently expressed (2). LMP1 has profound effects on
gene expression through its effects on multiple signaling pathways
(3). It is considered a member of the tumor necrosis factor recep-
tor (TNFR) family and interacts with TNFR-associated factors
(TRAFs) to constitutively activate NF-B, Jun N-terminal protein
kinase (JNK), and phosphoinositol kinase (PI3K) (4, 5). LMP1 is
required for B-cell transformation (6).
LMP1 has two domains that both activate NF-B, carboxy-
terminal activating domains 1 and 2 (CTAR1 and CTAR2) (7).
LMP1-CTAR1 is sufficient for fibroblast transformation, while
CTAR2 is dispensable (5, 6). CTAR1 also uniquely induces expres-
sion of several cellular genes, including the epidermal growth fac-
tor receptor (EGFR), TRAF1, ICAM1, and EBI3 (8, 9). Activation
of NF-B is complex and has two primary pathways that mediate
activation. The canonical pathway is regulated by the IB kinase
(IKK) complex that consists of IKK, IKK, and IKK (also called
NEMO) (10). This complex phosphorylates the inhibitor of NF-
B, IkB, that is sequestered in the cytoplasm. This phosphoryla-
tion induces IkB degradation and results in the release of dimers
of p50 with p65 (RelA). The noncanonical pathway is thought to
be largely regulated by NIK which phosphorylates and activates
the IKK kinase, leading to the processing of the p100 precursor
to p52 which then associates with RelB to bind and activate tran-
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scription (11). LMP1-CTAR2 has the strongest NF-B activation
properties in reporter assays, while CTAR1 uniquely activates
noncanonical NF-B signaling and strongly induces the process-
ing of p100 to p52 (12–14).
The effect of activation of NF-B by LMP1 has been particu-
larly informative in the C33 cell line. This cell line has very low
levels of endogenous NF-B activity, and expression of LMP1 in
C33 cells revealed that LMP1 induced multiple distinct NF-B
forms using electrophoretic mobility shift assays (EMSA) includ-
ing abundant p50 dimers, p50/p52 dimers, and p65 (12, 15). Ad-
ditionally, LMP1-CTAR1 induced high levels of expression of the
epidermal growth factor receptor in C33 cells, and studies using
chromatin immunoprecipitation (ChIP) indicated that CTAR1
induced a complex containing p50 dimers and the transactivator
bcl3 on the EGFR promoter (8, 16). These effects are mediated in
part through the increased expression of bcl3 that is induced by
CTAR1 through effects on Stat3 (17). Stat3 is phosphorylated on
both tyrosine and serine; however, previous studies using ChIP
and an antibody to phosphorylated Ser474 detected Stat3 on the
BCL3 promoter and within a BCL3 intron (17). Importantly, a
recent study has indicated that p50/bcl3 is the major form of
NF-B detected in NPC (18).
In the study reported here, the unique effects of LMP1-CTAR1
on cellular gene expression were further analyzed using mRNA
sequencing. Additionally, the binding of bcl3, p50, and phosphor-
ylated Stat3 (pStat3) was determined using ChIP in combination
with high-throughput sequencing (ChIP-Seq). More than 13,000
genes were identified by high-throughput RNA sequencing
(RNA-Seq) with a read per kilobase per million (RPKM) of 0.1.
Ingenuity pathway analysis of the genes that were changed more
than 2-fold revealed significant enrichment for genes involved in
cancer and pathways related to cellular movement, survival,
growth, and proliferation and cell-to-cell signaling. Multiple
components that regulate the NF-B pathway were affected.
ChIP-Seq identified CTAR1-specific bcl3 binding for more than
1,000 genes with approximately 90% of the peaks detected
within the probable promoter region. Analysis of the genes iden-
tified by the bcl3 ChIP indicated that many of the genes contrib-
uted to regulation of the integrin signaling, protein ubiquitina-
tion, epithelial mesenchymal transition pathways, extracellular
signal-regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) pathway, and the stat3 pathway. Interestingly, TRAF1,
ID proteins, NFKB1, and NFKB2 were identified in the bcl3 ChIP,
confirming that some of the unique effects of CTAR1 on cellular
gene expression are mediated by this important NF-B member.
RESULTS
Identification of LMP1-CTAR1 effects on expression. The effect
of LMP1-CTAR1 on cellular gene expression in C33 cells has been
previously analyzed using expression microarray analysis (19).
This approach revealed few changes in gene expression greater
than 2-fold and did not identify the EGFR, although EGFR tran-
scription was determined to be increased 8-fold using quantitative
PCR and 20-fold by RNase protection. To identify other changes
using current, more-sensitive technology, total RNA was prepared
from three preparations of C33 cells expressing LMP1-CTAR1 or
the pBabe vector control. The RNA was used to prepare 6 cDNA
libraries that were bar coded and pair end sequenced. The se-
quences were aligned to the human genome (hg19) using the
TOPHAT program in the Galaxy suite. Aligned reads were
mapped to more than 23,000 cellular genes using the Partek
Genomics Suite. Of the 13,292 genes with expression greater than
0.1 reads per million per kilobase (RPMK), 120 were increased
2-fold with a P of 0.05, while 244 were increased 1.5-fold.
Decreased expression was identified with 211 genes changed 2-
fold and 280 genes decreased 1.5-fold. Changes in expression
were compared to other studies that analyzed the effects of LMP1
on cellular expression or analyzed cellular expression in LMP1-
positive or -negative NPC samples (see Table S1 in the supple-
mental material) (19–27). Multiple genes that have been previ-
ously shown to be decreased by array analysis in other systems had
significantly decreased expression in the presence of LMP1-
CTAR1 including TNF superfamily member 10 (TNFSF10) (44-
fold), glycoprotein M6A (GPM6A) (13-fold), laminin 1
(LAMA1) (12-fold), actin binding LIM protein 1 (ABLIM1)
(5-fold), and TNFR superfamily 19 (TNFRSF19) (4.6-fold)
(Table S1). Previously identified genes with increased expression
included BIRC3 (cIAP2) (182-fold), ENPP2 (47-fold), EGFR
(9-fold), RGS2 (8.5-fold), NFKB2 p100 (6.6-fold), the eph-
rin receptor B1 (EPHB1) (4.7-fold), NFKBIA (IB) (4.5-
fold), RELB (3-fold), and NFKBIZ (2.9-fold) (Table S1). The
significantly increased expression of NFKB2 and RELB suggests
that LMP1 activates the noncanonical pathway not only through
inducing the processing of p100, but also through effects on the
expression of p100 and RELB.
Ingenuity pathway analysis (IPA) of all genes changed 2-fold
with significant P values of 0.05 identified cancer as the most
significant disease or disorder with cellular proliferation, cellular
movement, and cell signaling pathways predicted to be activated
(Table 1). IPA predicted cell death/apoptosis of tumor cells and
cellular protrusions to be negatively regulated. These functions
had activation z scores where the absolute value greater than 2 is
considered highly statistically significant. IPA analysis also indi-
cated that the affected targets could represent potential activation
of multiple pathways. Canonical pathways that were statistically
significant included inhibition of matrix metalloproteases, death
receptor signaling, caveolar mediated endocytosis, HIF1 signal-
ing, TNF signaling, NF-B, and PTEN signaling (Fig. 1). Not un-
expectedly considering LMP1 is a constitutively activated member
of the TNF receptor family, both TNFR1 and TNFR2 were iden-
tified as canonical pathways (4). Activation of the HIF1 pathway
has previously been shown to be activated by LMP1 and the genes
identified as CTAR1-specific targets in the HIF1 pathway in-
cluded MMP3, MMP14, MMP10, and caveolin (28).
IPA was also employed to identify genes that would likely reg-
ulate the genes shown to be affected by CTAR1. Genes identified as
potential upstream regulators for genes changed 1.5-fold in tran-
scription included TNF (P value  1.89E24), but also included
CHUK (IKK), TRAF2, and glutathione synthase 3 (GSK3B)
which are predicted to be activated, and MAP3K7 (TAK1) which
is predicted to be inhibited (Table 2). The significant z score for
CHUK (IKK)likely reflects its critical role in activation of the
noncanonical NF-B pathway. Interestingly, CD40 was also iden-
tified as a likely activated upstream regulator. CD40 and LMP1 are
thought to be closely related, as both bind the same TRAF mole-
cules and LMP1 can partially substitute for CD40 loss in geneti-
cally engineered mice (29, 30). Other NF-B family members,
NFKB1 p105, MAP3K14 (NIK), NFKBIA (IB), and NFKB2
p100 were also identified as possible upstream regulators with less
significant z scores. Additional potential upstream regulators with
Edwards et al.
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highly significant P values, indicative of considerable overlap with
genes in the target data set, included HRAS, STAT3, CTNNB1
(-catenin), PTEN, EGR1, PIK3R1, MAP3K1 (MEK), MAPK1
(ERK2), VEGFA, ID1, TRAF3, ERBB4, PRKC, and JUNB. Acti-
vations of STAT3, ERK, and PI3 kinase have been previously
shown to be induced by LMP1-CTAR1 (5, 31, 32). LMP1-CTAR1
also binds TRAF3 and increases expression of ID1. These data
strengthen our current understanding of LMP1 signaling and ad-
ditionally identify potential targets that are affected by LMP1-
CTAR1. LMP1 has been suggested to modulate -catenin, and
this analysis identifies multiple other proteins that are regulated
similarly to -catenin through potential effects on GSK3B, in ad-
dition to many genes regulated by -catenin (33, 34) (Table 2).
Chromatin immunoprecipitation and sequence alignment.
Based on the considerable induction of EGFR in C33 cells and the
identification of p50 and bcl3 bound to the EGFR promoter and
the induction of bcl3 by activated Stat3, additional binding sites
for bcl3, p50, or pStat3, were mapped using ChIP-Seq (16, 17).
Chromatin immunoprecipitation (ChIP) was performed from
two biological replicates of C33 cells expressing CTAR1 using an-
tibodies to p50, bcl3, and pStat3. Previously known binding sites
within the EGFR promoter were precipitated with the p50 and
bcl3 antibodies and from sites in the introns of BCL3 for pStat3
(Fig. 2).
Libraries from immunoprecipitated DNA were prepared, se-
quenced, and aligned to the human genome using Bowtie. Ap-
proximately 11 million reads were mapped in both the pBabe (pB)
vector control and CTAR1 (CT1)-expressing cells from DNA pre-
cipitated with bcl3 antibody. From this, 5,860 peaks with a false
discovery rate (FDR) of less than 10 were identified in the pB-
containing cells of which 4,520 peaks (77%) localized to genes,
while 2,095 peaks were identified in the CTAR1-expressing cells
with 96% localized to genes (Fig. 3A). Even though fewer binding
sites for bcl3 were identified in the CT1 ChIP, 25% overlapped a
bcl3 peak in ENCODE, while only 14% of the sites identified in pB
overlapped known bcl3 binding sites (Fig. 3A). Of the 2,012 bcl3
peaks in CTAR1-expressing cells that mapped to genes, 1,488 peaks
were identified in common with the control cells, and 524 peaks
were unique to CTAR1. The 4,520 peaks identified in the pB-
containing cells included the 1,488 peaks in common with CTAR1
and an additional 3,032 peaks that were detected only in the pB-
containing cells (Fig. 3B). bcl3 was detected on a total of 3,921
genes in the vector control cells, with bcl3 binding to 1,584 of these
genes in CT1-expressing cells either at the same site or a different
site within the gene. bcl3 also bound to an additional 2,337 genes
in pB-containing cells (Fig. 3C). A number of the genes had mul-
tiple binding sites for bcl3, reflected in the total number of peaks
being more than the genes bound by bcl3 (Fig. 3B and C). A total
of 2,589 genes were bound by bcl3 in the CTAR1-expressing cells
with 1,005 genes uniquely bound by bcl3 in these cells. The greater
number of genes over the number of peaks in the CTAR1-
expressing cells reflects the possible binding to more than one
gene at the same site due to genes on both strands or more than
one gene in the same direction. Many of the bcl3 peaks in the
CTAR1-expressing cells were detected within the promoter re-
gions with another gene on the opposite strand. Thus, one binding
site could affect more than one gene (Fig. 3B and C). Both of these
analyses indicate that LMP1 induces a shift in the binding of bcl3
to additional and fewer genes and that a portion of the constitu-
tively bound bcl3 remains bound in the presence of LMP1.
In contrast to the ChIP-Seq data with bcl3, considerable p50
and pStat3 binding was detected across the genome; however,
none of the peaks for either p50 or Stat3 had an FDR of 10.
Although this decreases the confidence of the peaks identified, the
high FDR likely reflects both the quality of the antibodies used for
ChIP-Seq and the considerable number of peaks. The transcrip-
tion binding of p50, Stat3, and bcl3 at sites overlapping those in
ENCODE are listed for the genes identified in the RNA-Seq anal-
ysis in Table S1 in the supplemental material.
Effects of bcl3 on transcription regulation. To identify bind-
ing to the promoters of specific genes, the promoter was defined to
include from position 2000 to the transcription start site. Ap-
FIG 1 Canonical pathways associated with genes with 2-fold expression change by RNA-Seq in CTAR1-expressing C33a cells. Significant canonical pathways
determined by IPA analysis of the genes with 2-fold change in expression by RNA-Seq in the CTAR1-expressing cells are shown. The height of the bars reflects
the P value, and the orange boxes reflect the ratio of the number of genes in the data set that are represented in the pathway.
Edwards et al.
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proximately 88% of the LMP1-CTAR1 enriched bcl3 bound se-
quence peaks were detected within the promoter with only 1%
within an exon, 4% within an intron, and 7% intergenic. In con-
trast, only 38% of the peaks in the pB-containing control cells
were detected within the promoter, 32% within an intron, and
23% intergenic (Fig. 3A). Analysis of genes previously linked to
CTAR1 included ID1 and ID3, two genes known to be uniquely
induced by LMP1-CTAR1. Although the expression of these genes
was essentially unchanged, both genes have peaks with FDRs of
10 within the promoter in the bcl3 ChIP-Seq with peaks that
overlap those in the ENCODE data set (Table 3). ID1, ID2, ID3,
and ID4 were bound by bcl3 in both the LMP1-CTAR1-
expressing and pB-containing cells; however, the peaks had many
more reads in the CTAR1-expressing cells, and all had low FDRs
(Table 3). Numerous members of the NF-B pathway were bound
by bcl3 in the CTAR1-expressing cells, including the IB kinase
(NEMO), the NF-B inhibitors IB, IB, IB, IB, IB	,
TBK, NFKB1 (p50), NFKB2 (p52), and RelA. Even though the
peaks called for some of these genes had FDRs greater than 10, the
peaks for IB, IB, IB, IB	,NFKB1, and NFKB2 overlapped
bcl3 sites identified in ENCODE. bcl3 binding was also detected
on several MAPK members, including TAK1, ERK2, and
MAP3K8 (COT) (FDRs of 10), as well the PI3K members
PIK3R1 and PIK3R3. The bcl3 sites in MAP3K8 and PIK3R1 also
overlapped ENCODE bcl3 peaks. Additionally, sites near TRAF1,
TRAF2, and TRAF6 were detected in the bcl3 ChIP. GSK3B,
ICAM1, and RIPK1 were also identified by bcl3 ChIP with the sites
for GSK3B and RIPK1 overlapping ENCODE peaks (Table 3).
Additional genes that have been previously linked to CTAR1 that
had slightly less significant P values in the RNA-Seq data but were
not ChIPed by bcl3 included TNFAIP3 (A20) (4.6-fold), TRAF3
(1.4-fold), and TRAF5 (1.2-fold) (Table 3). Of note, many of
the genes that had bcl3 peaks overlapping ENCODE bcl3 peaks
had only slight expression changes detected by RNA-Seq (Ta-
ble 3). This may indicate that bcl3 can bind sites but requires
additional factors to modulate transcription. Genes with changes
in expression with significant P values in the RNA-Seq and bcl3
sites identified in ENCODE included NFKBIA, NFKBIZ, NFKB2,
and MAP3K8.
Visual inspection of the mapped reads in the bcl3 ChIP-Seq in
comparison to the peaks identified by the MACS (model-based
binding analysis for ChIP sequencing) program and with peaks for
bcl3 from ENCODE revealed surprising differences (Fig. 4).
NFKB2 (p100/p52) was increased 6.6-fold at the transcriptional
level with a P value of 0.003. Examination of the mapped reads
across NFKB2 indicated two strong peaks, which were called as a
single peak with an FDR of 10, that overlapped with peaks from
ENCODE (Fig. 4). NFKB1 (p105/p50) was increased only 1.42-
fold with a not significant P value of 0.19. However, a large, wide
peak for bcl3 was identified by MACS with an FDR of 8; this peak
overlapped with the ENCODE peak. NFKB1A (IkB) increased
4.5-fold transcriptionally (P  0.05) and also had a broad peak
with an FDR of 10 that overlapped with two peaks identified in
ENCODE. In contrast, the ID proteins, ID1, -2, and -3, all had
strong peaks called by MACS with low FDRs but were not signif-
icantly affected as determined by RNA-Seq. TRAF1, which has
been previously shown to be uniquely induced by LMP1-CTAR1,
was increased 1.6-fold by RNA-Seq with a not significant P value.
TRAF1 had a strong, clear peak at the promoter identified by
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CODE sites, one of which was 4 kb 5= to the promoter and the
other was within an exon. Similarly, ICAM1 which has been
shown to require CTAR1 was increased 2.5-fold by RNA-Seq with
a P value of 0.06 and had two peaks, one of which was called by
MACS with an FDR of 10 and the other overlapped a site iden-
tified in ENCODE. In keeping with previous studies, the tran-
scription of EGFR was increased 9-fold. Both p50 and bcl3 have
been previously shown to bind the EGFR and were identified in
this study in the initial PCR of the ChIPed chromatin for known
binding sites; however, peaks for bcl3 or p50 were not identified by
the MACS program. Visual inspection of the bcl3 binding for
EGFR identified a major broad peak that extended into the first
kilobase of the gene. A smaller peak with approximately 5-fold
enrichment was also present at the promoter that spanned the
sequences used for the initial chromatin PCR. This initial ampli-
fication detected 4- to 7-fold enrichment in the LMP-CTAR-
expressing cells. Thus, the peak observed by ChIP-Seq was in






































































pB IgG pB Stat3 CT1 IgG CT1 Stat3
FIG 2 Quantitative PCR of known binding sites of the transcription factors on chromatin. To confirm the success of the ChIP, the sample chromatin from the
pBabe (pB)- and CTAR1 (CT1)-expressing cells was subjected to quantitative PCR for known target/binding sites of the transcription factors. For the bcl3 and
p50 ChIPs, primer pairs were used to amplify known binding sites within the EGFR promoter, EGFR-pro and KB2. For the pStat3 ChIP, primer pairs were used
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FIG 3 Distribution of bcl3 peaks. (A) Distribution of peaks with FDRs of 10 across the genome, those mapped to genes (within 2 kb of start site or within
intron or exon) and those that overlap ENCODE bcl3 peaks. (B) Overlap of bcl3 peaks between the pB-containing and CT1-expressing cells. (C) Overlap of genes
ChIPed by bcl3 in the pB-containing and CT1-expressing cells.
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icant. These findings suggest that many potential binding sites
may be called with poor statistics (FDRs) and that visual inspec-
tion of peaks for genes significantly affected transcriptionally may
provide additional insight.
All genes whose expression was changed at least 1.5-fold that
are listed in Table S1 in the supplemental material were visually
inspected. Genes identified by ChIP with an FDR of 10 are pre-
sented in one column, while genes identified with an FDR of 10
that had major peaks are listed in an adjacent column. Interest-
ingly, for genes with an FDR of 10, the CTAR1 peaks had an
average increase of 9-fold (ranging from 4 to 20) over the back-
ground IgG, while the pB peaks averaged 3-fold over IgG (ranging
from 2 to 5). This difference in peak intensity is exemplified by the
peaks for ID2 (Fig. 4). The strong, broad peak based on 120 reads
for CTAR1 had an FDR of 4, while the small pB peak, based on 30
reads, had an FDR of 2 (Table 3). For peaks with FDRs of 10, the
CTAR1 peaks averaged 7.2-fold (ranging from 4 to 17) over IgG,
while the pB peaks averaged 3-fold (ranging from 2 to 4). This
visual inspection revealed that the small pB peaks were much
more likely to have low FDRs compared to the high, broad peaks
induced by CTAR1 (Table S2). Comparing the visually curated
peaks with genes with significant changes in expression revealed
that pB and CTAR1 had approximately the same percentage of
genes (11% and 13%, respectively) with decreased expression and
ChIPed by bcl3. In contrast for genes with increased expression,
manual curation of peaks indicated that for CTAR1 approxi-
mately 25% of genes with increased expression were bound by
bcl3, while pB had only 8% of genes with increased expression
bound by bcl3 (Table S2). This analysis suggests that in the pres-
ence of CTAR1, binding of bcl3 increases transcription.
Based on the greater confidence in the bcl3 data, IPA analysis
was used to further characterize the pathways potentially regu-
lated through bcl3 based on genes with peaks with FDRs of 10.
Common significant canonical pathways shared between the vec-
tor control cells and the CTAR1-expressing cells included integrin
signaling, protein ubiquitination, molecular mechanisms of can-
cer, PI3K/AKT signaling, and ERK/MAPK signaling, with addi-
tional genes involved in these pathways detected with bcl3 only in









No. of reads in CT1
by peak calling FDR
No. of reads in pB for the
same peak as for CT1 by
peak calling FDR
bcl3 ID1 0.69 1.15 134 2 28 2
bcl3 ID2 0.47 1.25 103 4 30 2
bcl3 ID3 0.86 1.06 184 2 40 3
ID4 0.09 1.42 167 5 46 2
CHUK (IKK) 0.68 1.04
IKBKB (IKK) 0.19 1.10 10 4
IKBKE (IKK) Not expressed
IKBKG (NEMO/IKK
) 0.66 1.06 64 10
MAP3K14 (NIK) 0.05 1.97
bcl3 NFKBIA (IB) 0.05 4.50 113 10
bcl3 NFKBIB (IB) 0.85 1.02 48 10
bcl3 NFKBID (IB) 0.71 1.11 98 7 19 6
NFKBIE (IB) 0.23 1.27 62 10
bcl3 NFKBIZ (IB	) 0.01 2.98 77 9 53 3
TBK1 0.44 1.06 105 5 100 3
bcl3 TAB1 0.14 1.18 62 10
bcl3 NFKB1 (p50) 0.19 1.42 113 8
bcl3 NFKB2 (p52) 0.003 6.65 109 10
bcl3 RELA 0.35 1.04 135 5
RELB 0.01 3.00
MAP2K3 (MEK3) 0.19 1.16 80 10
MAP2K6 (MEK6) 0.11 1.90
MAP3K7 (TAK1) 0.37 1.10 54 10
MAPK1 (ERK2) 0.003 1.20 101 10
bcl3 MAP3K8 (COT) 0.04 1.70 124 10
bcl3 PIK3R1 0.24 1.13 139 3 47 2
PIK3R3 0.16 1.33 156 3 35 6
RB1 0.58 1.07 47 10
TRAF1 0.32 1.60 75 10
TRAF2 0.21 1.14 118 10
TRAF3 0.18 1.39
TRAF5 0.17 1.23
TRAF6 0.81 1.04 70 7 20 4
BCL3 0.48 1.24 111 10
bcl3 GSK3B 0.77 1.03 119 10
ICAM1 0.06 2.5 36 10
bcl3 RIPK1 (RIP) 0.98 1.01 131 4 41 3
TNFAIP3 (A20) 0.07 4.64
EGFR 0.03 9.0
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CTAR1-expressing cells (Table 4). Additionally, several canonical
pathways that were only specifically significant in the CTAR1-
expressing cells for bcl3 genes with FDRs of 10 were identified.
These pathways included STAT3, TGF signaling, and the regula-
tion of epithelial-mesenchymal transition (Table 4).
The ChIP-Seq data identified numerous genes (2,589 in
CTAR1-expressing cells) that had bcl3 binding with an FDR of
10, but only a small subset of these genes had significant expres-
sion changes by RNA-Seq (1.0%). Of the 524 genes with expres-
sion changes of 1.5-fold, only 25 had corresponding peaks in the
bcl3 ChIP. To ascertain whether any of the remaining 499 genes
with significant expression changes (1.5-fold) that were not
ChIPed but were potentially regulated indirectly through bcl3,
IPA analysis was utilized to identify possible upstream regulators
of these genes. IPA identified 785 possible upstream regulators for
these genes of which 159 (20%) were ChIPed by bcl3 in CTAR1-
expressing cells. As indicated in Table 2, many of the major pre-
dicted upstream regulators for all 1.5-fold genes were ChIPed by
bcl3. Genes that were identified with an FDR of 10 included
NFKB1, HRAS, CTNNB1 (-catenin), PTEN, EGR1, PIK3R1,
ID1, and ERBB4. Additional potential regulators that were pre-
dicted and had bcl3 peaks with an FDR of 10 included TRAF2,
GSK3B, NFKBIA (IB), MAP3K1 (MEK), and MAPK1 (ERK2).
These findings suggest that LMP1-CTAR1-mediated effects on
bcl3 are responsible for multiple CTAR1-specific effects on ex-
pression. Other potential regulators that were identified with sig-
nificant P values but were not bound by bcl3 included TRAF3,
STAT3, MAP3K14 (NIK), and PRKCD (PKC) (Table 2). These
potential regulators are in agreement with identified properties of
LMP1-CTAR1, which is known to bind TRAF2 and TRAF3 and
activate NIK and protein kinase C (PKC) (4, 32, 35).
DISCUSSION
This is the first comprehensive RNA-Seq analysis of genes whose
expression is modulated only by the CTAR1 domain of LMP1 in
the C33 cell line. LMP1-CTAR1 has the unique ability to activate
the noncanonical pathway of NF-B, represented by p52/relB
dimers. In the C33 cell line that has little endogenous activation of
NF-B, electrophoretic mobility shift assays (EMSA) had revealed
that CTAR1 induced at least 3 distinct complexes, including a
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FIG 4 Visualization of bcl3 peaks called by MACS. A representation of peaks called for bcl3 in the CT1-expressing and pB-containing cells, showing the height
of the peak, location on the genome, gene bound, and bcl3 peaks in the ENCODE database. The gene is listed with the fold change by RNA-Seq and the FDR of
the peak called by MACS for the CT1-expressing cells. For the EGFR gene, the locations of primers used to check chromatin for known NF-B sites are shown.
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prominent p50/p50 homodimer. Additionally, several genes have
been shown to be uniquely activated by LMP1-CTAR1, including
EGFR, TRAF1, and ICAM1. Both TRAF1 and ICAM1 were in-
creased more than 1.5-fold in the RNA-Seq analysis and bound by
bcl3, but with poor FDRs. Surprisingly, transcription of EGFR was
increased 9-fold, and both p50 and bcl3 were identified by initial
PCR of the ChIPed chromatin for known binding sites; however,
peaks for bcl3 or p50 were not called with the MACS program.
This disparity with the ability to identify the EGFR promoter be-
tween ChIP and the ChIP-Seq data may reflect the complexity of
the ChIP-Seq data and the bioinformatics analysis.
LMP1-CTAR1, but not LMP1-CTAR2, is also sufficient for
transformation of rodent fibroblasts and has the unique ability to
activate PI3 kinase, which is required for rodent fibroblast trans-
formation (5). In this study, the robust analysis of the effects on
cellular transcription determined by high-throughput RNA se-
quencing revealed that the transcription of most genes was not
affected by LMP1-CTAR1 and that more genes had reduced ex-
pression than increased expression. Importantly, analyses of the
pathways represented by these genes are in concordance with
many of the biological effects of LMP1 expression. It is known that
LMP1-CTAR1 binds multiple ubiquitin ligases, including TRAF2,
-3, and -5 and A20 (4, 36). Thus, ubiquitin-mediated changes in
protein levels or location may contribute to the potent biological
effects of LMP1-CTAR1.
Several genes whose expression was increased by LMP1-
CTAR1 were also identified in a similar screen of LMP1-CTAR2
(TES2) in 293 cells using expression microarrays (27). The LMP1-
TABLE 4 Significant canonical pathways of bcl3 ChIPed genesa
Ingenuity canonical
pathway P value Ratiob Genesc
Integrin signaling 1.3E06 2.18E01
44/202
RAP1B, RAP2B, RAP2A, RALA, ARPC1B, ARHGEF7, PIK3R1, ARPC5, SOS2, RHOT2,
HRAS, CRK, BCAR1, PTEN, NCK2, ARF6, ACTR3, PPP1R12A, MAP2K2, SOS1,
RHOU, TSPAN4, RHOF, MAP2K1, ACTN1, ITGB1, PIK3C2B, ACTR2, NRAS,
ASAP1, ARPC5L, CRKL, ACTB, TNK2, BCAR3, ACTG1, GIT1, RAC3, PIK3R3,





FZR1, USP45, PSMA7, USP20, UBE2V2, FBXW7, USP48, USP7, UBE2D4, USP10,
UBE2E3, DNAJC9, DNAJC19, BIRC6, USP19, DNAJC25, UBE2S, DNAJB14, TRAF6,
UBE2G2, USP32, ZBTB12, RBX1, UBE2G1, SMURF2, VHL, UBE2I, USP21,
DNAJC10, DNAJA1, USP39, ANAPC1, UBE2F, SMURF1, UCHL1, USP3, USP13,
DNAJC4, USP42, HSPE1, AMFR, UBE2M, PSMD13, PSMA1, HSPD1, USP22,





EPN3, RAP1B, MYH10, ARPC1B, TGFBR3, ARPC5, HRAS, CRK, PTEN, NOTCH2,
ACTR3, BAIAP2, TUBA1C, JUP, CTNNB1, ACTN1, ACTR2, EPN1, TUBB3, NRAS,
ARPC5L, TUBB4B, ACTB, FGFR1, TUBB2A, ACVR1, ACTG1, TUBA1B, RRAS2,





RAP2B, CDKN2A, JAK1, BAD, APH1B, FZD3, PIK3R1, SOS2, TAB2, HRAS, MYC,
BBC3, MAP2K2, ARHGEF11, RASA1, RALGDS, PIK3C2B, SMAD2, CASP3,
RALBP1, RELA, RAC3, PIK3R3, PTPN11, RABIF, IRS1, PLCB3, CYCS, FNBP1,
RAP1B, RAP2A, RALA, ARHGEF7, LRP6, RHOT2, CRK, NFKB1, E2F3, CDKN2B,
PRKAG1, EP300, CASP6, BMPR1A, SOS1, SMO, RHOU, SMAD4, CTNNB1, RHOF,
MAP2K1, PRKDC, CDC25C, NRAS, ARHGEF12, GNAS, DVL1, GNAQ, BAX,





ACTR2, TUBB3, RALA, ARPC1B, ARPC5L, TUBB4B, ACTB, MAPRE1, TUBB2A,
ARPC5, TUBA1B, ACTG1, ARF6, ACTR3, ARPC1A, TUBB6, TUBA1C, MAPRE2,
CTNNB1, ACTN1, ARPC4
PI3K/AKT signaling 7.2E04 2.03E01
25/123
ITGB1, RELA, NRAS, JAK1, BAD, PIK3R1, SOS2, YWHAZ, HRAS, INPPL1, NFKB1,
PTEN, YWHAQ, SYNJ2, PIK3R3, PPP2CB, RRAS2, MAP2K2, TSC2, SOS1, FOXO3,
RPS6KB2, CTNNB1, MAP2K1, MCL1
ERK/MAPK signaling 5.6E03 1.66E01
31/187
RAP1B, PPP1CC, BAD, PIK3R1, SOS2, HRAS, CRK, BCAR1, PRKAG1, EP300,
YWHAQ, MYC, MAP2K2, CREB1, SOS1, STAT1, MAP2K1, JMJD7-PLA2G4B,
ITGB1, PIK3C2B, NRAS, VRK2, CRKL, YWHAZ, HIST2H3C (includes others),
RAC3, PIK3R3, PPP2CB, PPP1R3D, RRAS2, PPP1R12A
STAT3 pathwayd 1.0E03 2.33E01
17/73
SOCS1, NRAS, PTPN2, TGFBR3, FGFR1, HRAS, IGF2R, MYC, MAP3K12, MAP3K10,
RRAS2, MAP2K2, BMPR1A, PDGFRA, FGFRL1, SOCS7, MAP2K1
TGF- signalingd 3.1E03 2.07E01
18/87
SMAD2, NRAS, SOS2, ACVR1, HRAS, SMURF1, EP300, TRAF6, RRAS2, AMH,
MAP2K2, BMPR1A, RUNX2, SOS1, SMAD4, SMURF2, MAP2K1, ACVR2A




RELA, ID2, JAK1, FZD3, PIK3R1, SOS2, HRAS, NFKB1, SMURF1, NOTCH2,
MAP2K2, SOS1, SMO, SMAD4, CTNNB1, MAP2K1, SMAD2, PIK3C2B, NRAS,
FGFR1, EGR1, DVL1, PYGO2, PIK3R3, FZD8, DVL2, RRAS2, PTPN11, APH1B,
FGFRL1, FGF22, MAP2K5
a A total of 2,589 genes were unique and common to CTAR1-expressing cells. A total of 3,921 genes were unique and common to pB-containing cells.
b Ratio indicates the percentage of genes in a pathway that were also ChIPed by bcl3 in CT1-expressing cells (expressed exponentially); number of genes ChIPed in CTAR1-
expressing cells/number of genes in the pathway.
c Genes unique to CTAR1-expressing are shown in bold type.
d Pathway statistically significant to CTAR1-expressing cells and not vector control (pB-containing) cells.
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CTAR1 effects on transcription were considerably less compared
to CTAR2-mediated transcriptional effects which were almost en-
tirely regulated by NF-B (27). Additionally, many genes affected
by CTAR1 had expression changes opposite to those identified in
cells expressing CTAR2 (TES2) (see Table S1 in the supplemental
material). Of the top 32 genes with the greatest fold increase, rang-
ing from 182-fold to 5-fold in CTAR1-expressing cells, only 4 were
increased by CTAR2 (Table S1). Of the approximately 100 genes
whose expression was decreased in the presence of CTAR1 from
525-fold to 5-fold, only 9 genes were affected by CTAR2, and of
these, expression of 8 genes actually increased (27). These com-
parisons suggest that CTAR1 and CTAR2 have very distinct effects
on cellular gene expression. The decreased effects of LMP1-
CTAR1 on transcription compared to LMP1-CTAR2 may indi-
cate that CTAR1 mediates many of its effects posttranscription-
ally.
Comparison of the genes identified in the RNA-Seq analysis
with those genes identified by ChIP-Seq indicated that a subset of
CTAR1-regulated genes is potentially regulated by bcl3. Genes
bound by bcl3 in the vector control cells were equally upregulated
or downregulated, while binding of bcl3 in the LMP1-CTAR1-
expressing cells was much more likely to upregulate gene expres-
sion (see Table S2 in the supplemental material). Importantly,
many of the genes whose expression was affected had predicted
upstream regulators that were ChIPed by bcl3 or cellular proteins
known to be modulated by LMP1-CTAR1, including TRAF2,
TRAF3, -catenin, and PI3 kinase (Table 2). Interestingly, the
ubiquitin ligase CYLD, which negatively regulates bcl3 nuclear
localization, was increased 2.7-fold in the RNA-Seq analysis (Ta-
ble S1) (37). The potential decrease in bcl3 nuclear accumulation
may be responsible for the detection of fewer genes that were
bound by bcl3 in the CTAR1-expressing cells. The predicted acti-
vation of TRAF2 and the upregulation of NIK would result in the
activation of the noncanonical NF-B pathway, and also, both p52
and relB expression were increased by LMP1-CTAR1 (Fig. 5).
These findings suggest that the noncanonical pathway represented
by p52/relB may be responsible for many of the transcriptional
effects of CTAR1.
The ChIP data with p50 and STAT3 had poor false discovery
rates with no genes identified with an FDR of 10. These data are
likely indicative both of antibody quality and broad nonspecific
DNA binding. However, several factors suggest that much of the
data is specific. Surprisingly, the pattern of binding between
LMP1-CTAR1-expressing cells and the vector control cells was
considerably different such that only one of the p50 identified
peaks was in common with the peaks in the vector control cells.
This finding suggests that LMP1-CTAR1 completely altered the
binding sites of p50 (data not shown). Sequence alignment of the
sequences bound to p50 identified 7,746 peaks that contained p50
peaks induced in the presence of LMP1-CTAR1 compared to
1,594 peaks detected by p50 in the control cells. Additionally,
many of the genes bound in LMP1-CTAR1-expressing cells had
multiple p50 sites. Comparison with ENCODE data which is
based on ChIP of p65 (relA) revealed that 50% of the pBabe p50
FIG 5 LMP1 signaling through CTAR1. LMP1-CTAR1 binds TRAF1, -2, -3, and -5. TRAF2 and -3 recruit cIAP1 (Birc2) which targets TRAF3 for degradation,
thereby releasing NIK from TRAF3 negative regulation. NIK is ubiquitinated and stabilized and now available to activate IKK, which in turn phosphorylates
p100 leading to p100 processing to p52, and its subsequent translocation with RelB into the nucleus where the complex will bind DNA and increase transcription
of the bound genes. Through activation of PI3K by CTAR1, the increased levels of Map3K8 (Cot) are activated leading to phosphorylation and activation of NIK
and its downstream effects. Activated Map3K8 also leads to the processing of p105 to p50 and its subsequent translocation to the nucleus where it can bind with
bcl3 to turn on transcription or when bound as homodimers or heterodimers with p52, suppress transcription. The increased CYLD expression would lead to
deubiquitination of bcl3 and prevent bcl3 nuclear accumulation. A decrease in canonical NF-B signaling would result from the decreased expression of TAK1
and the increased expression of IB. Genes ChIPed by bcl3 with a FDR of 10 and/or match ENCODE peak are indicated by an asterisk. Solid green or red
arrows reflect changes in expression with P  0.05 in RNA-Seq data. Dashed green or red arrows reflect changes in expression with P  0.05 in RNA-Seq data.
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ChIPed sites matched p65 sites (data not shown). In contrast, of
the LMP1-CTAR1-induced p50 sites, only 6% have been previ-
ously identified by ChIP for NF-B p65 in ENCODE. This sug-
gests that p65 is the binding partner for p50 in the pBabe-
containing cells representing canonical NF-B signaling, while
other NF-B members are the likely binding partners for p50 in
CTAR1-expressing cells. These peaks could represent binding of
p50 homodimers or p50 with relB or p52, both of which were
increased by CTAR1 expression (Table 3). The expression of many
genes was decreased in the presence of CTAR1 despite the in-
creased expression of p50 and p52. This finding may reflect the
binding of heterodimers of p50/p52 or homodimers of p50/p50
which can bind DNA yet lack a transcriptional transactivation
domain and are thought to inhibit transcription (Fig. 5) (38).
Similarly to the dramatic effects of LMP1-CTAR1 on p50 bind-
ing, 6,327 peaks were identified as serine phosphorylated Stat3
binding sites in CTAR1-expressing cells, and 3,382 peaks in the
vector control cells with only 27 of these peaks in common be-
tween the CTAR1-expressing cells and the vector control cells.
This again suggests unique effects on the transcription factor
STAT3 in the presence of LMP1. Only 6% of these pStat3 sites in
the CTAR1-expressing cells have been identified as Stat3 sites in
ENCODE which used antibody for total Stat3. This likely suggests
that serine phosphorylated Stat3 represents a discrete subset of
Stat3 binding or that the phospho-serine Stat3 site is less accessible
to antibody.
The MEME Suite was used to identify any motifs in the collec-
tion of the bcl3, p50, and pStat3 precipitated sequences (39). A
consensus site was not identified within the bcl3 peaks possibly
due to the broadness of the peaks; however, the consensus NF-B1
site was identified for the p50 precipitated sequences in the
CTAR1-expressing cells (see Fig. S1 in the supplemental material).
Interestingly, the identified consensus site for p50 matched the
recently identified CTAR1-mediated change in the p50 binding
site (40). The unbiased MEME predictions and the completely
distinct binding between the CTAR1-expressing cells and the vec-
tor control cells suggest that the p50 and pStat3 ChIP data are
reflective of actual binding (Fig. S1). Table S1 reveals that many of
the genes with decreased expression in the LMP1-CTAR1-
expressing cells had p50 and pStat3 binding sites that have been
authenticated in ENCODE. In contrast, genes with increased ex-
pression were more likely to be detected by bcl3.
The multiple effects of LMP1-CTAR1 are summarized in
Fig. 5. Significant transcriptional upregulation was detected for
NFkB2/p100, RelB, and NIK which are the major components in
the noncanonical NF-B pathway. Additionally, cIAP, A20, and
MAP3K8 (COT) were also upregulated and likely contribute to
the activation of this pathway. Less significant transcriptional in-
creases were also indicated for TRAF1, -2, -3, and -5, which are
known to directly bind LMP1-CTAR1. Interestingly, the tran-
scriptional profile suggests potential negative regulation of canon-
ical NF-B with considerable increased expression of IB and
NFKBIZ (IB	),a novel member of the IB family, shown to in-
hibit transactivation and DNA binding of p65 (Table 3) (41). IPA
also predicted negative regulation of TAK1, which has been shown
to activate the IKK complex (42). Additionally, there were no
significant changes in expression of members of the IKK complex,
or TRAF6 and RIP, both of which uniquely interact with LMP1-
CTAR2.
The bcl3 ChIP also indicated that this transcription factor con-
tributes to many of the unique properties of LMP1-CTAR1. bcl3
peaks that overlap ENCODE bcl3 peaks were detected for NFKB2
(p100), COT, and IB The ID proteins previously shown to be
induced by CTAR1 were also detected in the bcl3 ChIP with sites
that overlap ENCODE bcl3 peaks. LMP1-CTAR1 also activates
PI3 kinase, and both PIK3R1 and PIK3R3 were bound by bcl3. In
summary, these data indicate that some of the very distinct prop-
erties of LMP1-CTAR1 are linked to its effects on bcl3 with IPA
prediction that the LMP1-CTAR1 effects are reflective of changes
induced by TNF, PI3 kinase, NFkB1 and NFkB2, CD40, NIK,
TRAF3, GSK-3, and -catenin, all of which are known to be
affected by LMP-CTAR1. Although relatively few genes had sig-
nificant changes in transcription, these effects are predicted to
affect pathways critical to cell growth. These data also suggest the
potential importance of the transcriptional inhibition due to p50/
p50- and p50/p52-mediated repression (Fig. 5). It is surprising
that many of the significant biological properties of LMP1 reside
in the CTAR1 domain despite the significant transcriptional ef-
fects induced by CTAR2 through canonical NF-B signaling. It is
known that LMP1-CTAR1 binds multiple TRAFs that are ubiqui-
tin ligases and also binds the dual ubiquitinating/deubiquitinating
A20 protein which was transcriptionally increased 4.6-fold. This
understanding and the limited number of transcriptional changes
suggest that LMP1-CTAR1 likely has considerable effects on the
cellular proteome not only through changes in protein abundance
but also potentially through unique ubiquitin linkages that affect
both cellular location and formation of protein complexes.
MATERIALS AND METHODS
Cell culture and cell lines. C33A, cervical carcinoma, stable cell lines ex-
pressing CTAR1 (amino acids 1 to 231) or vector control pBabe were
established as previously reported (19) and were cultured in Dulbecco’s
modified Eagle’s medium (Gibco) supplemented with 10% fetal bovine
serum (Sigma) and antibiotic/antimycotic (Gibco) and 1 g/ml puromy-
cin (Sigma) at 37°C with 5% CO2.
ChIP analysis. Chromatin immunoprecipitation (ChIP) analysis was
performed for two biological replicates using a ChIP kit (Millipore Magna
ChIP A/G) according to the manufacturer’s protocol. Briefly, cells were
cultivated in 150-mm plates to 90% confluence. The cells were fixed for
10 min in 1% freshly made formaldehyde, washed with phosphate-
buffered saline (PBS), and lysed for 15 min on ice in lysis buffer provided
in the kit. Chromatin was sheared by sonication to an average size of ~200
to 500 bp and clarified. Chromatin was incubated with normal rabbit
immunoglobulin G, with anti-bcl3 (sc-185x; Santa Cruz), anti-p50
(ab7971-1; Abcam), or anti-phospho-STAT3 (Ser727) (Cell Signaling
9134) at 4°C overnight on a nutator. Protein A/G magnetic beads were
added, and the samples were incubated at 4°C for 2 h on a nutator. The
antibody/DNA/magnetic bead complexes were thoroughly washed, the
protein/DNA complexes were eluted, and the cross-linking was reversed
by proteinase K digestion for 2 h at 62°C to free the DNA. Sample DNAs
were purified for further analysis according to the manufacturer’s proto-
col. For ChIP-seq samples, DNA from ChIP was submitted to the Univer-
sity of North Carolina High Throughput Sequencing Facility for library
preparation and high-throughput sequencing. Single-end 50-bp se-
quences were generated from each library using the Illumina HiSeq 2000
platform.
PCR of known target sites. To confirm the success of the ChIP, the
sample DNAs were subjected to quantitative PCR for known target/bind-
ing sites of the transcription factors. PCR was performed with Quantifast
SYBR green kit (Qiagen). For the bcl3 and p50 ChIPs, primer pairs used to
amplify known binding sites within the EGFR promoter were as follows:
5= GGGGACCCGAATAAAGGAGCAGTTT 3= and 5= CTGAGGAGTTA
ATTTCCGAGAGGGG 3= for EGFR-pro and 5= AGGGTCCCGTAGTGC
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TGCA 3= and 5= ACTGGCCGAGCCTTAGAGCCA 3= for KB2. For the
pStat3 ChIP, primer pairs used to amplify known binding sites within the
bcl3 gene were as follows: 5= TGACCCGGACTCAACCCCAG 3= and 5= T
CTCCTCCCCTCCTCTCCCTC 3= for bcl3-promoter, 5= CGCTTCCTC
CAACCTTAACC 3= and 5= TGCCCAGTCCCTAACCTCTT 3= for HS3,
and 5= CATTCGAGGATGGAAGTTGG 3= and 5= CAGGGTTAAGTGA
GGGCAGA 3= for HS4.
ChIP-Seq analysis. The resulting sequences were mapped to the ref-
erence human genome (University of California Santa Cruz [UCSC])
hg19 using Bowtie, a short-read aligner, in Galaxy (43). Binding sites
(peaks) were identified using the MACS (model-based binding analysis
for ChIP sequencing) program, a Poisson-based method, with a P value
cutoff of 105. Only binding sites within the full-length RefSeq gene,
exon, intron, and promoter region defined as 2 kb from the transcrip-
tional start site were retained. To annotate the peaks, the gene information
tracks, UCSC gene, available at UCSC genome browser was utilized.
ENCODE peaks for the transcription factors bcl3, NF-B (RelA), and
Stat3, also available at UCSC table browser were utilized for comparison
of peaks identified in this study to previously identified transcription fac-
tor regulation sites (ENCODE Uniform TFBS, ENCODE/SYDH [Stan-
ford/Yale/USC/Harvard], and ENCODE/HAIB [Hudson Alpha Insti-
tute]). Peaks were visualized using Integrative Genomics Viewer (IGV).
Binding motif identification. To find statistically enriched sequence
motifs within the ChIP-Seq peak regions, the MEME web application
was utilized (http://meme.nbcr.net/meme). The position weighted ma-
trix (PWM) generated by MEME was then represented in the log format
using Web logo http://weblogo.berkley.edu/logo.cgi to generate consen-
sus sequences for multiple cellular bcl3, p50, or pStat3 binding sites. To
determine whether the enriched motifs potentially overlapped known
transcription factor recognition motifs, the identified motifs were
matched with JASPER core database (http://jaspar.genereg.net) using the
TOMTOM program in MEME.
RNA-Seq. Total RNA was purified using RNeasy kit (Qiagen) and then
treated with DNase. Illumina RNA TruSeq libraries (average size, 300 bp)
were prepared from triplicate RNA samples by the University of North
Carolina Genomics Core and were sequenced by the North Carolina High
Throughput Sequencing Facility. Paired-end 50-bp sequences were gen-
erated from each library using the Illumina HiSeq 2000 platform. The
resulting sequences were mapped to the human genome (hg19) using
Tophat for Illumina in Galaxy. The resulting mapped reads were mapped
to annotated genes and statistically analyzed with Partek Genomics Suite.
Ingenuity analysis. For pathway analysis, all genes annotated in ChIP-
Seq and RNA-Seq were analyzed using Ingenuity Systems IPA software.
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